The latest news from Arcinova

May 6, 2019

Dr Stephen Byard receives Award for Service

Morpeth’s Dr Stephen Byard has received The Royal Society of Chemistry Aw
April 27, 2019

Industry Insights with… Paul Quigley

To coincide with CPhI North America 2019, we asked our Head of Drug Substance, Paul Quigley, to share his thoughts on the changing CDMO sector. The latest blog in our Industry Insights series high
April 26, 2019

Accelerating the path to first-in-human clinical trials

Our Head of Drug Substance, Paul Quigley, was recently interviewed by Outsourcing Pharma to coincide with his presentation at CPhI North America 2019. He explained the importance of ensuring rapid
April 17, 2019

Article: Chemistry 4.0 in pharmaceutical development

"The pharmaceutical industry is being revolutionised by the utilisation of digital technologies. Chemistry 4.0 describes this digital transformation and how its delivery is paving the way for the
April 16, 2019

Crédit d'impôt recherche Grants Arcinova with R&D Status

Arcinova has been recognised and approved by the Crédit d'impôt recherche (CIR) as an organisation undertaking R&D activities.  This will bestow significant benefits upon any French cus
April 8, 2019

Industry Insights with… Samuel Bourne

Welcome to the latest blog in our Industry Insights series, where we ask our experts to share their extensive expertise on topics within the pharmaceutical industry. We recently asked our Process
March 18, 2019

Investigating multi-dimensional problems in drug substance

"Finding solutions to the biggest challenges faced during drug substance development relies on properly integrating analytical and production expertise." Our CSO, Gareth
March 12, 2019

Industry Insights with… Stephen Byard

Welcome to our Industry Insights series, where we provide a platform for our scientists to share their extensive knowledge of subjects within pharmaceutical development. In the first blog of this
February 18, 2019

Panel discussion on Pharma and Chemical Supply Chain

Our CSO, Gareth Jenkins, took part in a panel discussion on the pharmaceutical supply chain. He offered his insights on the key issues and trends shaping the industry and the fac